Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study

Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study

Objectives: Tenofovir alafenamide (TAF) is a preferred nucleotide reverse transcriptase inhibitor used in the treatment of HIV. Co-administration of TAF with rifabutin (RFB) is not recommended due to concerns that RFB decreases TAF gastrointestinal absorption. The objective of this study was to dete...

Full description

Bibliographic Details
Main Authors:	Thomas C.S. Martin, Lucas A. Hill, Michael E. Tang, Shannon M. Balcombe
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	International Journal of Infectious Diseases
Subjects:	Tenofovir alafenamide HIV Rifabutin Co-administration
Online Access:	http://www.sciencedirect.com/science/article/pii/S1201971220321391

Similar Items

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
by: Nicholas T. Funderburg, et al.
Published: (2016-11-01)

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort
by: Bernard Surial, et al.
Published: (2019-10-01)

Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service
by: Dane Turner, et al.
Published: (2019-12-01)

Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide
by: Linden Lalley-Chareczko, et al.
Published: (2020-03-01)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01)

Distribution Evaluation of Tenofovir in the Breast Milk of Mothers With HBeAg-Positive Chronic HBV Infection After Treatment With Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate by a Sensitive UPLC-MS/MS Method
by: Na Yang, et al.
Published: (2021-08-01)

Changing trends in lipid profile and biomarkers of renal function and bone metabolism before and after switching from tenofovir disoproxil fumarate to tenofovir alafenamide: a prospective observational study
by: Mahoko Ikeda, et al.
Published: (2021-05-01)

Tenofovir alafenamide nephrotoxicity: a case report and literature review
by: Thornthun Ueaphongsukkit, et al.
Published: (2021-08-01)

Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis
by: Kento Inada, et al.
Published: (2021-09-01)

Darunavir–cobicistat–emtricitabine–tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era
by: Squillace N, et al.
Published: (2018-10-01)

Efficacy of tenofovir alafenamide in treatment of hepatitis B virus: A meta-analysis and non-inferiority evaluation
by: Qiu-Ran Wang, et al.
Published: (2021-06-01)

Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
by: Pierre-Emmanuel Plum, et al.
Published: (2021-09-01)

Renal proximal tubulopathy in an HIV-infected patient treated with tenofovir alafenamide and gentamicin: a case report
by: Jack E. Heron, et al.
Published: (2020-08-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Co-crystals, Salts or Mixtures of Both? The Case of Tenofovir Alafenamide Fumarates
by: Hannes Lengauer, et al.
Published: (2020-04-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)

Tenofovir Alafenamide Rescues Renal Tubules in Patients with Chronic Hepatitis B
by: Tomoya Sano, et al.
Published: (2021-03-01)

Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV
by: Ashana Puri, et al.
Published: (2019-04-01)

Multispecies Evaluation of a Long-Acting Tenofovir Alafenamide Subdermal Implant for HIV Prophylaxis
by: Manjula Gunawardana, et al.
Published: (2020-11-01)

RP-HPLC method development and validation for the estimation of Emtricitabine, Bictegravir and Tenofovir alafenamide in bulk and pharmaceutical dosage form
by: Tej Kumar Kokkirala, et al.
Published: (2019-12-01)

Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients
by: Brian T Lee, et al.
Published: (2021-02-01)

Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report
by: Ruochan Chen, et al.
Published: (2021-07-01)

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
by: Simone Perazzolo, et al.
Published: (2020-12-01)

Incidence and association of renal dysfunction with a long term Tenofovir-based therapy among HIV-positive naïve cohort at Ronald Ross Hospital
by: Enock Wantakisha, et al.
Published: (2020-06-01)

On the Single-Crystal Structure of Tenofovir Alafenamide Mono-Fumarate: A Metastable Phase Featuring a Mixture of Co-Crystal and Salt
by: Jian-Wei Wang, et al.
Published: (2020-12-01)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
by: Linying Li, et al.
Published: (2020-11-01)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
by: Leah M. Johnson, et al.
Published: (2019-07-01)

Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks
by: Kyle E. Korolowicz, et al.
Published: (2021-09-01)

Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF-β1/Smad3 signaling pathway
by: Lingxia Li, et al.
Published: (2019-07-01)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
by: Sarah M Michienzi, et al.
Published: (2021-07-01)

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV
by: Nicole Marie Lioufas, et al.
Published: (2018-06-01)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
by: Carolina Arana Stanis Schmaltz, et al.
Published: (2019-02-01)

Spherical amorphous nanoparticles loading with antituberculosis substance rifabutin
by: A. P. Kaplun, et al.
Published: (2010-04-01)

Unmet need in chronic hepatitis B management
by: Lilian Yan Liang, et al.
Published: (2019-03-01)

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease
by: Thomas Dick, et al.
Published: (2020-02-01)

Rifabutin-based Fourth and Fifth-line Rescue Therapy in Patients with for Helicobacter pylori Eradication Failure
by: Jihee Sung, et al.
Published: (2017-02-01)

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis
by: Christopher B. Toomey, et al.
Published: (2020-04-01)

Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
by: Wei Jing, et al.
Published: (2017-09-01)

Commentary: Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
by: Sandeep Sharma, et al.
Published: (2017-11-01)

Development and Validation of an Up-to-Date Highly Sensitive UHPLC-MS/MS Method for the Simultaneous Quantification of Current Anti-HIV Nucleoside Analogues in Human Plasma
by: Amedeo De Nicolò, et al.
Published: (2021-05-01)